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Abstract Although endometrial cancer is surgicopathologically
staged, preoperative imaging is recommended for diagnostic
work-up to tailor surgery and adjuvant treatment. For preopera-
tive staging, imaging by transvaginal ultrasound (TVU) and/or
magnetic resonance imaging (MRI) is valuable to assess local
tumor extent, and positron emission tomography-CT (PET-CT)
and/or computed tomography (CT) to assess lymph node metas-
tases and distant spread. Preoperative imagingmay identify deep
myometrial invasion, cervical stromal involvement, pelvic and/
or paraaortic lymph node metastases, and distant spread, how-
ever, with reported limitations in accuracies and reproducibility.
Novel structural and functional imaging techniques offer visual-
ization of microstructural and functional tumor characteristics,
reportedly linked to clinical phenotype, thus with a potential for
improving risk stratification. In this review, we summarize the
reported staging performances of conventional and novel preop-
erative imaging methods and provide an overview of promising
novel imaging methods relevant for endometrial cancer care.
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Introduction
Endometrial cancer is the most common gynecologic malig-
nancy in high-income countries, and the incidence is increas-
ing [1]. Most patients are diagnosed at an early stage with
tumors still confined to the uterine corpus in around 75 %.
However, after primary surgery, around 15–20 % of these
tumors recur in the vagina/pelvis (∼ one third of recurrences)
or at distant sites (∼ two thirds of recurrences) [2]. The overall
5-year survival of endometrial cancer for all stages is around
80 % [3]; however, in the metastatic setting, the prog-
nosis is dismal with reported median survival of only
7–12 months [4].
Adjuvant treatment and follow-up after primary surgery for
endometrial cancer has since 1988 been guided according to
the surgical International Federation of Gynecology and
Obstetrics (FIGO) staging systems, which was last revised in
2009 [5]. In addition to risk classification based on investiga-
tion of preoperative uterine biopsies, conventional imaging
methods, i.e., transvaginal ultrasound (TVU), magnetic reso-
nance imaging (MRI), computed tomography (CT), and pos-
itron emission tomography-CT (PET-CT) have, however,
long been employed at many centers in order to improve the
optimization of risk classification to tailor primary surgical
procedure and systemic therapeutic strategy [6]. Although
these imaging methods may provide information about likely
tumor stage based on conventional imaging findings (e.g.,
signs of deep myometrial invasion, cervical stromal invasion,
and pelvic and/or paraaortic lymph node metastases), the
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reported accuracies for preoperative staging of endometrial
cancer by conventional imaging have not yet been good
enough to be accepted to replace surgical staging including
lymphadenectomy, in particular for high-risk histology, at
many centers.
Novel functional imaging methods within US, MRI and
PET-CT, have long gained increasing interest, representing
promising additional imaging tools in the characterization of
various cancers, including endometrial cancers [7•, 8, 9•,
10–14, 15•, 16]. These advanced imaging methods may en-
able visualization and quantification of functional and micro-
structural tumor characteristics that may be closely linked to
c l i n i c a l p h e n o t y p e , t umo r s t a g e , p r o g n o s t i c
histomorphological tumor markers, and eventually outcome
[9•, 10, 13, 14, 17]. Thus, both conventional and functional
imaging may potentially provide preoperative imaging bio-
markers in endometrial cancer relevant for treatment and prog-
nosis that could be translated into the clinic to improved risk
stratified for individualizing patient treatment. This has the
potential to increase clinical benefit through reducing costs
and side effects from unnecessary overtreatment in low-risk
patients in combination with maintaining the optimal and
more comprehensive therapeutic strategy for high-risk
patients.
This review provides an overview of current conventional
and novel imaging methods for preoperative staging of endo-
metrial cancer and their corresponding reported staging per-
formances. The promising role of novel functional imaging
methods to yield potential new imaging biomarkers for im-
proved preoperative risk stratification in endometrial cancer is
also discussed.
Treatment and Staging of Endometrial Cancer
Primary surgical treatment of endometrial cancer is clinically
guided by a range of approaches to predict surgical FIGO
stage by estimating risk for lymph node metastases and distant
spread from endometrial biopsies and preoperative imaging
(Table 1). For putative FIGO stage I (tumor confined to the
uterine corpus) in low-risk endometrial cancer (endometrioid
adenocarcinoma grades 1 and 2 with myometrial infiltration
<50 %), with low risk for lymph node spread (Table 1), the
surgical procedure is normally limited to simple hysterectomy
and bilateral salpingo-oophorectomy (BSO), whereas in
intermediate- and high-risk endometrial cancer (endometrioid
adenocarcinomas, grades 1 and 2 with myometrial infiltration
≥50 %; endometrioid adenocarcinomas, grade 3; and non-
endometrioid adenocarcinomas), pelvic and paraaortic
lymphadenectomy/lymph node sampling may be included
and sometimes also omentectomy [2]. For endometrial can-
cers invading the cervical stroma (FIGO stage II), extended
hysterectomy, BSO, and pelvic lymphadenectomy are
recommended. For putative FIGO stage III (local or regional
tumor spread) and IV (distant metastases and/or invasion of
the bladder/bowel), surgical treatment is typically individual-
ized consisting of surgical tumor resection including
debulking of lymph nodes and metastatic lesions sometimes
after neoadjuvant therapy [2].
Surgical FIGO stage is the single strongest prognostic fac-
tor in endometrial cancer with a significant decrease in
disease-specific survival in patients with the higher stages.
Reported figures on 5-year survival for the different FIGO
stages are 90–96 % in stage IA (tumor confined to the uterus
with tumor infiltrating <50 % of the myometrial wall), 78–
87 % in stage 1B (tumor confined to the uterus with tumor
infiltrating ≥50% of the myometrial wall), 48–56% in stage II
(tumor invading cervical stroma), 48–60 % in stage III (local
or regional tumor spread), and ∼20 % in stage IV (distant
metastases and/or invasion of the bladder/bowel) [31, 32].
Final risk estimation based on postoperative assessment of
hysterectomy specimen for histological subtype and grade,
and presence of deep myometrial invasion, cervical stroma
involvement and/or metastatic spread, guides the selection of
presumed high-risk patients subjected to adjuvant chemo-
and/or radiotherapy [2].
Conventional Diagnostic Imaging for Preoperative
Staging of Endometrial Cancer
Preoperative imaging is an essential part of the diagnostic
work-up in endometrial cancer and is pivotal to define a pre-
sumed FIGO stage (based on imaging findings) guiding the
primary surgical treatment in addition to other biomarkers
(Table 1). The diagnostic performances of preoperative imag-
ing methods for the identification of deep myometrial inva-
sion, cervical stroma invasion, and extrauterine disease in-
cluding lymph node metastases preoperatively (Table 2) are
critical if they are to safely guide a tailored surgical approach
in order to avoid unnecessary invasive procedures in low-risk
patients.
Transvaginal Ultrasound
TVU is typically performed by the treating gynecologist with
the advantage of being readily available and with low costs.
Valid ultrasound diagnostics is, however, inherently depen-
dent on a skilled examiner being able to obtain representative
images depicting the pathology of interest, and TVUmay thus
be especially prone to interobserver variation. The endometri-
al cancer tissue is typically depicted as hyper- or isoechoic
relative to the surrounding myometrium (Fig. 1a) and cervical
stroma invasion as thickened hyper- or isoechoic endometri-
um extending into the cervical canal and cervical stroma [33,
34, 35•]. The reported sensitivities (specificities) [accuracies]
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of TVU for the detection of deep myometrial invasion and
cervical stroma invasion are 71–85 % (72–90 %) [72–84 %]
and 29–93 % (92–94 %) [78–92 %], respectively (Table 2)
[33, 34, 35•, 36, 37]. Due to the small field of view and limited
depth of penetration using high-frequency vaginal ultrasound
probes, TVU is not considered suited for valid assessment of
pelvic and paraaortic lymph node metastases.
Computed Tomography
Contrast-enhanced (CE) CT of the thorax, abdomen, and pel-
vis is widely employed preoperatively for the detection of
lymph node metastases and distant spread in endometrial can-
cer. The primary tumors, when visible at CE CT, are typically
depicted as slightly hypodense relative to the surrounding
contrast-enhancingmyometrial tissue (Fig. 1b). For local stag-
ing, CE CT has long been considered inferior to MRI and
TVU [6] due to lower soft-tissue contrast resolution at CT,
and recent literature reporting diagnostic performance for lo-
cal staging parameters of CE CT is thus scarce (Table 2). A
recent study of 24 endometrial cancer patients comparing CE
CT with PET/CE CT for detection of pelvic and paraaortic
lymph node metastasis also showed significantly lower sensi-
tivity of CE CT than that of PET/CE CT, with reported sensi-
tivities for lymph node metastases of 29 and 57 %, respective-
ly [39].
Magnetic Resonance Imaging
Pelvic MRI has long been established as a valuable imaging
method in the preoperative staging of endometrial cancer [6,
44, 45]. Acquiring at least two T2-weighed sequences angled
perpendicularly of the uterus is routinely performed; T1-
weighted series with intravenous contrast is also normally
included in the protocol due to the reportedly better diagnostic
performance of CEMRI for identification of deep myometrial
invasion than that of non-contrast MRI [6, 45]. The optimal
contrast timing for diagnosing deep myometrial invasion is
∼2 min post contrast allowing the best discrimination between
tumor tissue and the outer myometrial muscular layer [46].
Endometrial cancers are typically slightly hyperintense on
T2-weighted images (Fig. 1c) and hypointense relative to the
normal highly vascularized myometrium on CE T1 weighted
images (Fig. 1d). The reported sensitivities (specificities) [ac-
curacies] of CE MRI for the detection of deep myometrial
invasion, cervical stroma invasion, and metastatic lymph
nodes are 33–100 % (44–100 %) [58–100 %], 33–69 %
(82–96 %) [46–89 %], and 17–80 % (88–100 %) [83–
93 %], respectively, based on articles published in the last
decade [37, 40, 41]. The broad range for these numbers on
diagnostic performance illustrates that although MRI is con-
sidered one of the best imaging methods for preoperative stag-
ing in endometrial cancer, the diagnostic performance of CE
MRI is still somewhat variable.
FDG PET-CT
Fluorodeoxyglucose (18F-FDG) PET-CT combines two im-
aging techniques visualizing both morphologic and metabolic
tumor characteristics at the same time-point allowing co-
registration of structural and functional data depicted in fused
images (Fig. 1g, h). PET-CT is increasingly employed in the
preoperative staging of many cancers, including gynecologic
cancers [7•, 37, 43, 47, 48]. The most common radiotracer is
FDG, a glucose analogue that preferentially accumulates in
malignant tissue due to its higher rate of glycolysis. Due to
limitations of spatial resolution, FDG PET-CT is, however,
unlikely to replace TVU and MRI for assessing pelvic disease
state for depth of myometrial and cervical stromal invasion.
For the detection of lymph node metastases and distant
spread, FDG PET-CT reportedly outperforms TVU and
MRI, thus representing a very promising preoperative imag-
ing method to differentiate between patients that are unlikely
to benefit from lymphadenectomy and those that may profit
from the procedure [47, 49]. The reported sensitivities
(specificities) [accuracies] of FDG PET-CT in the detection
Table 1 Reported impact of
histopathologic diagnosis and
selected additional biomarkers in
endometrial cancer for
preoperative prediction of extra
uterine disease (EUD) and
postoperative prediction of
survival. The increase (%) of
patients with EUD at diagnosis,
and decrease in 5-year survival
(%) based on pre- and
postoperative assessments of
biomarkers are listed
Biomarker EUD (%) Decrease in 5-year survival (%)
Preoperative biopsy Hysterectomy specimens
Non-endometrioid histology [1, 18–22] 50 23 40
Grade 3 [19–22] 11–18 17 28
Vascular invasion [21, 22] 20 NR 30
Loss of ER/PR expression [18, 23, 24] 24–27 30 20–30
P53 overexpression [25, 26] 23–49 21–38 30
Aneuploidy [19, 27–30] 22–25 12–22 19
References [18, 19] and [28] are prospective studies
EUD extra uterine disease including patients with lymph node metastases, NR not reported, ER estrogen receptor,
PR progesterone receptor, P53 tumor protein p53
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of lymph node metastases are 74–85 % (91–96 %) [89–93 %]
(Table 2) [7•, 37, 43]. The ability to correctly identify meta-
static lymph nodes is, however, largely affected by lymph
node size; node-based sensitivities of 100, 67, and 13 % in
metastatic nodes ≥10, 5–9, and ≤4 mm, respectively, were
























































































































































































































































































































































































































































































































































































































































































































































Fig. 1 Characteristic preoperative imaging findings in endometrial
cancer. VUS (a) in patient with FIGO stage 1B (endometrioid, grade 2)
depicting a large uterine tumor (arrows) with mixed echogenicity and
signs of deep myometrial invasion. CE CT (b), sagittal T2 weighted
MRI (c), axial CE T1-weighted MRI (d), axial DWI (b = 1000 s/mm2)
(e) with ADCmap (f), and FDG PET-CT (g) in a patient with FIGO stage
1B (endometrioid, grade 3). The large uterine tumor (arrows), invading
>50 % of the myometrial wall, is hypodense relative to the surrounding
myometrium at CT (b), hyperintense at T2-weighted MRI (c), and
hypointense at CE T1-weighted MRI. DWI shows tumor hyperintensity
(e) with corresponding hypointensity on the ADC map (f; mean ADC
value of 0.54 × 10−3 mm2/s), indicating restricted diffusion within the
tumor. The same lesion is FDG avid at FDG PET-CT (g; SUVmax of
10.4). FDG PET-CT in patient with FIGO stage 3C2 (endometrioid, grade
3) (h) depicts large FDG avid tumor (SUVmax of 25.0) and three pelvic
lymph node metastases (h, open arrows; SUVmax of 11.3). The bladder
(b) normally appears FDG avid due to FDG secretion in the urine (g).
Note the concomitant calcified myoma (m) seen at VUS (a) and the
adjoining myoma (m) depicted at MRI (d–f) with no restricted
diffusion; the myoma is thus easy to differentiate from the uterine
tumor. ADC apparent diffusion coefficient, B bladder, CE contrast
enhanced, CT computed tomography, DWI diffusion weighted imaging,
FDG fluorodeoxyglucose,Mmyoma,MRI magnetic resonance imaging,
PET positron emission tomography, SUV standard uptake value, VUS
vaginal ultrasound
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Novel Imaging Methods for Preoperative Staging
of Endometrial Cancer
Current intensive research efforts on novel imaging tech-
niques as well as new contrast agents or tracers may provide
improved imaging methods potentially enabling more accu-
rate depiction of tumor extent and better detection of metasta-
tic disease in endometrial cancer.
3D US
Three-dimensional (3D) ultrasound technology allows acqui-
sition of ultrasound images from an organ or tissue of interest
that may be reconstructed in any desired plane. This allows
further analysis including virtual navigation and 3D ultra-
sound volume calculations of e.g., tumor volume [51]. The
reported diagnostic performance of 3D ultrasound for assess-
ment of deep myometrial invasion was quite promising in a
study by Alcazar on endometrial cancer (n=96) reporting a
sensitivity (specificity) [accuracy] of 93% (82%) [85%] [38].
Interestingly, applying a cut-off for the shortest tumor-free
distance to serosa of ≤9 mm yielded a corresponding sensitiv-
ity (specificity) [accuracy] of 100 % (61 %) [72 %] for pre-
diction of deep myometrial invasion [38].
DWMRI
Diffusion weighted (DW) MRI is a functional imaging tech-
nique whereby contrast is derived from the random motion of
water molecules [40]. Restricted diffusion of water molecules
in the tissue is depicted as hyperintense on the high b value
DW images (Fig. 1e) with corresponding hypointensity on the
apparent diffusion coefficient (ADC) map (Fig. 1f). The dif-
fusion property of the tumors is considered a surrogate marker
for tumor cellularity as intact cells constitute a barrier to water
diffusion [52]. Endometrial cancers typically exhibit restricted
diffusion (Fig. 1e, f) with reported mean tumor ADC values in
the range of 0.75–0.97×10−3 mm2/s, being significantly low-
er than that reported for benign uterine lesions (1.21–
1.76 × 10−3 mm2/s) and normal endometrium/myometrium
(1.52–1.71×10−3 mm2/s) [40]. The reported diagnostic per-
formance of DW MRI for preoperative staging parameters in
endometrial cancer is in the range of those reported for CE
MRI (Table 1) [8, 40], and it has been advocated that CEMRI
may be safely omitted when including DWMRI in patients in
whom MRI contrast agents are contraindicated [53].
MRI with Lymph Node-Specific Contrast Agent
The use of lymph node-specific contrast agent based on ultra-
small particles of iron oxide (USPIO) has been shown to dra-
matically improve the diagnostic performance of MRI for the
detection of metastatic lymph nodes in endometrial and
cervical cancer with reported sensitivity (specificity) [accura-
cy] of 91–100 % (87–94 %) [88–95 %] [42]. However, this
contrast agent has unfortunately been withdrawn by the man-
ufacturer pending further validation before potential imple-
mentation in the clinic.
Potential Imaging Biomarkers in Endometrial
Cancer
A biomarker is defined as a Bcharacteristic that is objectively
measured and evaluated as an indicator of normal biologic
processes, pathogenic processes, or pharmacologic responses
to a therapeutic intervention^ [54]. Conventional imaging and
novel functional imaging methods may be employed to visu-
alize and quantify tumor extent as well as microstructural and
functional tumor characteristics that are closely linked to clin-
ical phenotype and histomorphological biomarkers. These im-
aging findings may serve as imaging biomarkers that may
potentially aid to improve risk stratification and to tailor ther-
apeutic strategy in endometrial cancer (Table 3).
Tumor Size
Pretherapeutic conventional imaging may yield clinically rel-
evant information regarding primary tumor size (Table 2)
[35•, 55, 60•, 61, 62]. The unfavorable prognostic impact of
large tumor size in endometrial cancers is consistently sup-
ported by both in vivo and ex vivo studies [61–65], but opti-
mal cut-off values for tumor size, based on preoperative im-
aging, for identification of high-risk patients are yet to be
defined. A recent study of preoperative MRI in endometrial
cancer patients found that anterioposterior (AP) tumor diam-
eter >2 cm and craniocaudal (CC) tumor diameter >4 cm sig-
nificantly predicted deep myometrial invasion and lymph
nodemetastases, respectively; and that both tumor size param-
eters were significantly associated with reduced recurrence
and progression-free survival [60•]. Similarly, volume index
(defined as products of maximum AP, transverse (TV), and
CC tumor diameters) >36 at preoperative MRI was reportedly
associated with lymph node metastases [62] and dismal prog-
nosis [61] in endometrial cancer. In line with this, tumor-free
distance to serosa (TFD) ≤9 mm at TVU predicts deep
myometrial invasion in endometrial cancer [38].
Transvaginal Ultrasound Tumor Echogenicity
and Doppler Parameters
Tumor echogenicity at preoperative TVU may provide addi-
tional information relevant for stage and prognosis in endo-
metrial cancer. Mixed or hypoechoic tumors are reportedly
more frequent in patients with deep myometrial invasion and
in grade 3 tumors [11], and non-regular endometrial–
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myometrial border at TVU also predicts deep myometrial in-
vasion [11, 35•]. Doppler parameters characterizing the vas-
cular tumor morphology may also be linked to stage and
grade. High color score and vascularization index (VI) are
reportedly more frequent in tumors with deep myometrial in-
vasion and in grade 3 tumors [11, 55]. One study proposed
cut-offs for the vascularization index for the prediction of deep
myometrial invasion and grade 3 tumors of VI >7 and VI
>10 %, respectively [55].
ADC Measurements Reflecting Tumor Microstructure
DWMRI with measurements of tumor ADC values may pro-
vide additional information about tumor microstructure with
potential relevance for staging and prediction of aggressive
disease. Low mean tumor ADC value is associated with deep
myometrial invasion [8]. Interestingly, high ADCq (defined as
the difference in ADC between the 25th and the 75th percen-
tile voxel in one lesion), putatively reflecting high intratumor
heterogeneity of water movement, is associated with deep
myometrial invasion, cervical involvement, lymph node me-
tastases, and lymphovascular space invasion [13]. Similarly,
minimum ADC value (ADCmin) of the primary tumor is re-
portedly lower in patients with deep myometrial invasion,
cervical involvement, and lymph node metastases, and in pa-
tients with grade 3 endometrioid subtype [14]. Furthermore,
ADCmin significantly predicted reduced disease-free surviv-
al, also after adjusting for FIGO stage [14], suggesting that
tumor ADC measurements may potentially yield additional
prognostic information aiding in risk stratification when
selecting patients for adjuvant treatment.
DCE-MRI Parameters Reflecting Tumor
Microvasculature
Dynamic contrast-enhanced (DCE) MRI is a novel functional
imaging technique allowing quantitative assessment of tissue
perfusion and vascular permeability, enabling characterization
of tumor microvasculature and the angiogenic profile of tumor
tissue in vivo [66]. Recent findings suggest that DCE-MRI
tumor parameters are significantly linked to specific clinical
and histological phenotypes in endometrial cancer [9•, 10].
Low tumor Fb (blood flow) and high tumor E (extraction
fraction; reflecting capillary leakage) predict reduced
recurrence/progression-free survival and are more frequent
in non-endometrioid tumors [10]. Interestingly, Fb is also re-
portedly inversely correlated to the expression of prognostic
immunohistochemical markers reflecting microvascular
Table 3 Potential preoperative imaging biomarkers in endometrial cancer
Imaging modality and/or parameter Imaging characteristics of primary tumor
predicting DMI and/or LNM and/or
aggressive disease
Possible link between imaging




Echogenicity Mixed or hypoechoic tumor predict DMI [11]
Non-regular endometrial–myometrial borders [35•]
Tumor heterogeneity and altered
tumoral texture
NR
Doppler parameters High color score [11], low resistive index, and
high peak systolic velocity [12], high VI [55]
Disorganized angiogenesis with
altered tumoral blood flow
VI >7 for DMI and VI >10
for grade 3 tumors [55]
MRI
ADC value (based on DWMRI) Low ADCmean predicts DMI [8], high ADCqa
predicts DMI and LNM [13], and low ADCmin
predicts aggressive disease [14]
Increased cellularity and intratumor
heterogeneity of water movement
ADCmean < 0.75 for DMI [8]
ADCmin < 0.66 for recurrence [14]
Blood flow (based on DCE-MRI) Low tumor blood flow predicts reduced recurrence/
progression-free survival [9•, 10]




Metabolic parameters: SUVmax, SUVmean,
MTV, and TLG
High tumor SUVmax, SUVmean, MTV, and
TLG predict DMI, LNM, and poor prognosis
[7•, 15•, 16, 17, 56, 57•, 58, 59]
Increasing metabolic activity of
malignant tumors
MTV > 20 for DMI and MTV > 30
for LNM [7•]
SUVmax > 9 [56] and >18 [17] and
MTV > 9 and TLG > 70 [16] for
high-risk
MTV > 17 and TLG > 56 for recurrence
[57•]
Tumor size (all imaging modalities) Large tumor diameters and large tumor volume
[7•, 16, 35•, 55, 57•, 60•, 61, 62]
Increased metastatic potential of
large tumors
Volume indexb > 36 for LNM [62]
and poor prognosis [61]
AP diameter >2 cm for DMI and CC
diameter >4 cm for LNM [60•]
TFD ≤9 mm for DMI [38]
ADC apparent diffusion coefficient (10−3 mm2 /s), AP anterioposterior, CC craniocaudal, DCE dynamic contrast enhanced, DMI deep myometrial
invasion, DW diffusion weighted, FDG fluorodeoxyglucose, LNM lymph node metastases, MRI magnetic resonance imaging, MTV metabolic tumor
volume (mL), NR not reported, PET positron emission tomography, SUV standard uptake value, TFD tumor-free distance to serosa, TLG total lesion
glycolysis (g), TV transverse, TVU transvaginal ultrasound, VI vascularization index (%)
a ADCq is defined as the difference in ADC between the 25th and the 75th percentile voxel in one lesion [13]
b Volume index is defined as products of maximum anterioposterior (AP), transverse (TV), and craniocaudal (CC) diameters (cm) [62]
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proliferation [9•]. Tumor hypoxia, which is a characteristic
feature of various solid tumors and believed to promote tumor
progression and resistance to therapy [67, 68], may thus play a
pivotal role in the pathogenic mechanisms leading to tumor
growth and metastatic spread, in endometrial cancer.
FDG PET-CT Parameters Reflecting Tumor Metabolism
Paralleling the well-documented feasibility of FDG
PET-CT for detection of lymph node metastases in en-
dometrial cancer, the potential value of FDG PET-
specific quantitative tumor parameters for predicting
clinical and histologic tumor characteristics in endome-
trial cancer has been increasingly explored [7•, 15•, 16,
17, 56, 57•, 58, 59, 69]. Tumor maximum standard
uptake value (SUVmax) is the most frequently reported
PET parameter; SUVmax representing the value of the
voxel with the highest SUV within the drawn volume
of interest (VOI) putatively represents tumor tissue
(Fig. 1g, h) [7•]. The VOI is typically manually drawn
using prespecified thresholds for SUV (e.g., SUV> 2.5)
of voxels to be included in the VOI, and metabolic
tumor volume (MTV) and mean SUV (SUVmean) are
calculated in this VOI. Total lesion glycolysis (TLG),
wh i c h i s d e r i v e d f r om SUVmean and MTV
(TLG=SUVmean ×MTV), represents a measure of total
viable tumor cells within the tumor, and TLG is in-
creasingly reported in studies on endometrial cancer
[7•, 16, 57•, 70].
High-tumor SUVmax, SUVmean, MTV, and TLG are uni-
formly reported to predict deep myometrial invasion, cervical
stroma invasion, lymph node metastases, and poor prognosis
in endometrial cancer [7•, 15•, 16, 17, 56, 57•, 58, 59, 69]. The
proposed cut-offs for these parameters to identify high-risk
patients have, however, a relatively wide range in the
literature: for SUVmax >9–18 [17, 56], for MTV >9–
30 mL [7•, 16, 57•], and for TLG >56–70 g [16, 57•]
(Table 3). This variation in proposed cut-offs for
predicting high-risk phenotype may be due to dissimilar
patient cohorts and lack of standardization of imaging
protocols and post-processing methods (e.g., manual
ROI placement and different threshold for SUV to be
included in the MTV) in the studies. Thus, further stud-
ies are needed to validate and better standardize meta-
bolic imaging parameters including optimized thresholds
for risk stratification for potential clinical use.
In Vivo MR Spectroscopy
In vivo MR spectroscopy (MRS) is a method to obtain bio-
chemical information non-invasively from biological tissue.
Within a selected volume of interest, typically tumor tissue,
signals from chemical nuclei in the tissue are registered; the
most commonly used nuclei are protons (hydrogen). MRS has
long been established as a valuable adjunct to conventional
MRI in the assessment of various tumors, e.g., tumors in the
brain, prostate, and breast [71]. Studies on MRS in endome-
trial cancer are scarce, but some studies have reported in-
creased signals from choline in endometrial cancer tumors
[72–75]. Interestingly, a recent study found that the choline/
water ratio increased with increasing tumor stage and large
tumor size in endometrial cancer [74]. Furthermore, another
choline-derived parameter, choline signal to noise ratio
(ChoSNR), is reportedly significantly higher in type 2 endo-
metrial cancers than that in type 1 endometrial cancer [75].
Altered choline profile in endometrial cancer has also been
demonstrated using high-resolution magic angle spinning
(HR-MAS) 1H nuclear magnetic resonance (NMR) tech-
niques on endometrial cancer biopsies [76], confirming the
central role of choline in the metabolic rearrangements subse-
quent to malignant transformation in endometrial cancer. The
potential value of choline as biomarker based on in vivoMRS
or HR-MAS of biopsies in endometrial cancer is, however,
largely unknown.
Textural Imaging Features
Texture analysis is an image post-processing technique
analyzing a set of quantified metrics to assess the spa-
tial arrangements of densities/intensities in a volume of
interest. Quantitative measures of image heterogeneity
have been shown to be closely linked to tissue markers
of heterogeneity, hypoxia, and angiogenesis and have
also been shown to predict survival for various cancers
[77]. Whether texture analysis of VUS, CT, MRI, and
PET may provide imaging biomarkers in endometrial
cancer is not yet established.
Novel PET Tracers
A wide range of novel PET radiotracers is currently being
developed with the aim of imaging relevant biological pro-
cesses and molecular targets in clinical oncology [78].
However, there is currently very limited experience with the
use of these novel tracers in endometrial cancer. PET imaging
of endometrial cancer with tracers specific for e.g., hypoxia,
cell proliferation, amino acid metabolism, angiogenesis,
apoptosis, blood flow, fatty acid metabolism, or estrogen
receptors may, however, lead to increased understanding
of the biologic processes relevant for tumor progression
and metastatic spread in endometrial cancer, and will be
particularly interesting to explore as predictive markers
sequentially during treatment with targeted and novel
therapeutics for early signs of response. Still, the imple-
mentation of novel PET tracers in endometrial cancer is
largely awaited.
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Interobserver Agreement for Preoperative Staging
and Reproducibility of Imaging Biomarkers
High interobserver agreement is crucial for evaluating the
usefulness of a diagnostic test, and the interobserver agree-
ment should ideally be systematically evaluated before intro-
duction of the test in the clinic. Quite variable interobserver
agreement for the evaluation of deep myometrial invasion by
VUS has been observed both among ultrasound experts and
among general gynecologists with reported kappa values of
0.24–0.81 and 0.26–0.71, respectively [79]. For VUS assess-
ment of cervical stroma invasion, the interobserver agreement
was also variable, however, with significantly better agree-
ment reported for ultrasound experts (kappa values of 0.35–
0.77) than for general gynecologists (kappa values of 0.05–
0.75) [79]. Varying interobserver agreement is also observed
at MRI for the evaluation of deep myometrial invasion, cervi-
cal stroma invasion, and lymph node metastases with reported
kappa values of 0.16–0.91, 0.46–0.77, and 0.36–0.74, respec-
tively [8, 41, 80, 81].
The reproducibility of tumor measurements that may be
used as potential imaging biomarkers should be thoroughly
assessed prior to implementation in the clinic, and the inter-
observer agreement for these measurements should ideally be
very good to warrant inclusion in risk stratification models.
VUS measurements of tumor-free distance (TFD) to serosa in
endometrial cancer reportedly yield very good interobserver
agreement with ICC of 0.91 [38]. For tumor size measure-
ments at MRI, the reported interobserver agreement is also
very good with ICC of 0.78–0.85 [60•], and tumor ADC value
measurements seem also quite robust with an ICC of 0.60 [8].
Reported ICC for measurements of SUVmax, SUVmean,
MTV, and TLG in endometrial cancer is 0.98, 0.87, 0.56,
and 0.57, respectively [7•]. The moderate agreement observed
forMTVand TLGmeasurements may be due to the subjective
steps involved in the manual placement of the VOI for esti-
mation of MTVand TLG.
Conclusions
Preoperative imaging is crucial in order to enable tailored
surgical procedure in endometrial cancer. Whereas TVU
and/or pelvic MRI are preferred for the assessment of local
pelvic tumor extent, PET-CT and/or CT may improve the de-
tection of lymph node metastases and distant spread. All im-
aging methods are, however, hampered by non-perfect accu-
racies for the staging parameters and limitations in reproduc-
ibility. Novel structural and functional imaging techniques,
visualizing microstructural and functional tumor characteris-
tics, may be closely linked to clinical phenotype, tumor stage,
and tumor biologic characteristics in endometrial cancer. Such
characteristics based on novel imaging techniques may thus
serve as future imaging biomarkers in endometrial cancer.
Importantly, potential new imaging biomarkers should be
thoroughly assessed for reproducibility and studied in relation
to currently standardly applied preoperative biomarkers from
e.g., endometrial biopsies, also documented to be hampered
by non-perfect accuracies in predicting disease spread
and poor outcome, and with well-documented limita-
tions in reproducibility. The potential added value from
novel imaging technique will need to be explored in the
context of the currently applied state of the art methods
for preoperative risk assessment to tailor endometrial
carcinoma treatment, also assessing costs and benefits
for different approaches to elucidate potential clinical
benefit from advanced imaging methods implemented
in clinical care.
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